$SER

Venkatesan Jay purchased $1K of SER

Venkatesan Jay purchased 589 shares of Serina Therapeutics, Inc. (SER) at $1.78 on 2026-05-22.

Original reporting
SEC EDGAR · Venkatesan Jay
Published Jun 22, 2026, 11:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SER
Bullish
medium confidence
Mentioned
$SER
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (589 shares at $1.7800; total $1,048.42) filed on 2026-06-22.

02

Market read

Traders may note the insider buy, but the disclosed dollar value is too small to be a standalone catalyst.

03

What to watch

No 10b5-1 plan and no follow-on pattern (only one transaction) limits inference about sustained insider conviction.

Relevance 4/10Novelty 2/10Timing: after-hours/filing timestamp (2026-06-22) for an SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction filing for Serina Therapeutics, Inc.

Company-level read

Ticker impact

$SERBullishMedium confidence
Context

Serina Therapeutics disclosed via SEC Form 4 that director Venkatesan Jay bought 589 shares at $1.7800 on 2026-05-22.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider buys can be read as confidence, but the disclosed size (~$1.0k) and lack of 10b5-1 plan detail make it low material for trading decisions.

Market effects

No sector read-through; this is a company-specific, small insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase is very small and may reflect personal liquidity/compensation rather than a strong forward-looking signal.

Key entities

  • Serina Therapeutics, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Venkatesan Jay

    Director who reported the open-market purchase.

Related articles